|
gptkbp:instance_of
|
gptkb:psychologist
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Lou_Gehrig
|
|
gptkbp:advocates_for
|
policy changes
increased awareness
funding for research
support for affected families
|
|
gptkbp:affects
|
motor neurons
|
|
gptkbp:associated_with
|
environmental factors
genetic factors
|
|
gptkbp:caused_by
|
muscle weakness
|
|
gptkbp:charity_work
|
gptkb:ALS_Therapy_Development_Institute
gptkb:Team_Gleason
gptkb:ALS_Association
gptkb:MDA_(Muscular_Dystrophy_Association)
|
|
gptkbp:clinical_trial
|
ongoing
investigating gene therapy
investigating new drugs
investigating stem cell therapy
|
|
gptkbp:community_impact
|
social isolation
financial burden
emotional stress
caregiver responsibilities
|
|
gptkbp:current_use
|
gptkb:frontotemporal_dementia
gptkb:primary_lateral_sclerosis
gptkb:DJ
pseudobulbar affect
|
|
gptkbp:famous_person
|
gptkb:Morrie_Schwartz
gptkb:Stephen_Hawking
gptkb:Lou_Gehrig
gptkb:David_Niven
|
|
gptkbp:first_described_by
|
1869
|
|
gptkbp:growth_rate
|
varies by individual
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lou Gehrig's Disease
|
|
gptkbp:is_often_used_in
|
adults aged 40 to 70
|
|
gptkbp:is_popular_in
|
varies by region
approximately 2 per 100,000 people
|
|
gptkbp:lifespan
|
2 to 5 years
|
|
gptkbp:named_after
|
gptkb:Lou_Gehrig
|
|
gptkbp:public_awareness
|
gptkb:ALS_Ice_Bucket_Challenge
|
|
gptkbp:receives_funding_from
|
private donations
federal grants
philanthropic organizations
|
|
gptkbp:research_focus
|
symptom management
causes
treatments
|
|
gptkbp:social_responsibility
|
neurological examination
|
|
gptkbp:symptoms
|
fatigue
difficulty speaking
difficulty swallowing
muscle cramps
|
|
gptkbp:treatment
|
medications
physical therapy
occupational therapy
speech therapy
|